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Summary
Background Psychological treatments for adolescents with unipolar major depressive disorder are associated with 
diagnostic remission within 28 weeks in 65–70% of patients. We aimed to assess the medium-term eﬀ ects and costs 
of psychological therapies on maintenance of reduced depression symptoms 12 months after treatment.
Methods We did this multicentre, pragmatic, observer-blind, randomised controlled superiority trial (IMPACT) at 
15 National Health Service child and adolescent mental health service (CAMHS) clinics in three regions in England. 
Adolescent patients (aged 11–17 years) with a diagnosis of DSM IV major depressive disorder were randomly assigned 
(1:1:1), via a web-based randomisation service, to receive cognitive behavioural therapy (CBT) or short-term 
psychoanalytical therapy versus a reference brief psychological intervention. Randomisation was stochastically 
minimised by age, sex, self-reported depression sum score, and region. Patients and clinicians were aware of group 
allocation, but allocation was concealed from outcome assessors. Patients were followed up and reassessed at weeks 6, 
12, 36, 52, and 86 post-randomisation. The primary outcome was self-reported depression symptoms at weeks 36, 52, 
and 86, as measured with the self-reported Mood and Feelings Questionnaire (MFQ). Because our aim was to compare 
the two psychological therapies with the brief psychosocial intervention, we ﬁ rst established whether CBT was inferior 
to short-term psychoanalytical psychotherapy for the same outcome. Primary analysis was by intention to treat. This 
trial is registered with Current Controlled Trials, number ISRCTN83033550.
Findings Between June 29, 2010, and Jan 17, 2013, we randomly assigned 470 patients to receive the brief psychosocial 
intervention (n=158), CBT (n=155), or short-term psychoanalytical therapy (n=157); 465 patients comprised the 
intention-to-treat population. 392 (84%) patients had available data for primary analysis by the end of follow-up. 
Treatment ﬁ delity and diﬀ erentiation were established between the three interventions. The median number of 
treatment sessions diﬀ ered signiﬁ cantly between patients in the brief psychosocial intervention group (n=6 
[IQR 4–11]), CBT group (n=9 [5–14]), and short-term psychoanalytical therapy group (n=11 [5–23]; p<0·0001), but 
there was no diﬀ erence between groups in the average duration of treatment (27·5 [SD 21·5], 24·9 [17·7], 27·9 [16·8] 
weeks, respectively; Kruskal–Wallis p=0·238). Self-reported depression symptoms did not diﬀ er signiﬁ cantly between 
patients given CBT and those given short-term psychoanalytical therapy at weeks 36 (treatment eﬀ ect 0·179, 95% CI 
–3·731 to 4·088; p=0·929), 52 (0·307, –3·161 to 3·774; p=0·862), or 86 (0·578, –2·948 to 4·104; p=0·748). These 
two psychological treatments had no superiority eﬀ ect compared with brief psychosocial intervention at weeks 36 
(treatment eﬀ ect –3·234, 95% CI –6·611 to 0·143; p=0·061), 52 (–2·806, –5·790 to 0·177; p=0·065), or 86 (–1·898, 
–4·922 to 1·126; p=0·219). Physical adverse events (self-reported breathing problems, sleep disturbances, drowsiness 
or tiredness, nausea, sweating, and being restless or overactive) did not diﬀ er between the groups. Total costs of the 
trial interventions did not diﬀ er signiﬁ cantly between treatment groups.
Interpretation We found no evidence for the superiority of CBT or short-term psychoanalytical therapy compared with 
a brief psychosocial intervention in maintenance of reduced depression symptoms 12 months after treatment. 
Short-term psychoanalytical therapy was as eﬀ ective as CBT and, together with brief psychosocial intervention, oﬀ ers 
additional patient choice for psychological therapy, alongside CBT, for adolescents with moderate to severe depression 
who are attending routine specialist CAMHS clinics.
Funding National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, and the 
Department of Health.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
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Research in context
Evidence before this study
Unipolar major depression emerges with the highest incidence 
risk rate in the second decade of life, aﬀ ecting a substantial 
proportion of the adolescent population worldwide. Good 
evidence exists for psychological treatments being associated 
with clinical remission in about 70% of cases. By contrast, data 
are scarce for whether one or more of the available therapies is 
associated with maintenance of reduced depressive symptoms 
1 year after the end of treatment. This issue is not trivial, 
because maintenance of depressive symptoms below a clinical 
threshold 12 months after the end of treatment is associated 
with reduced risk for diagnostic relapse into the adult years. We 
searched PubMed between Aug 1, 1990, and Aug 31, 2016, 
with the search terms “adolescence”, “depression”, 
“psychological treatments”, “randomised controlled trials”, 
“remission”, “relapse”, “relapse prevention”, and “adverse 
eﬀ ects”. This search identiﬁ ed three trials of school 
population-based interventions, a small (n=43) feasibility study 
of a social media intervention for relapse prevention in patients 
recovered from depression, and a Cochrane database review of 
relapse prevention in children and adolescents with depression. 
No identiﬁ ed psychological treatments are currently 
recommended as eﬀ ective in maintaining reduced depressive 
symptoms in the year after successful treatment.
Added value of this study
Our ﬁ ndings show that short-term psychoanalytical 
psychotherapy and CBT, delivered by highly trained therapists 
over 28 weeks and 20 weeks, respectively, were not superior to 
a reference brief psychosocial intervention delivered over 
12 weeks by child and adolescent psychiatrists and mental 
health nurses. All three psychological treatments were 
associated with an average 49–52% reduction in depression 
symptoms 1 year after treatment. Prescribing of an SSRI 
during therapy or follow-up, as per National Institute for 
Health and Care Excellence guidelines, did not diﬀ er between 
the treatment groups and so did not mediate the outcome. 
Suicide and self-harm attempts over the follow-up period 
were lower than at baseline, as were physical side-eﬀ ects. 
Furthermore, total costs and quality-of-life scores did not 
diﬀ er between treatment groups by the end of the study.
Implications of all the available evidence
To our knowledge, this is the only high-quality, fully 
powered, superiority and cost-effectiveness study assessing 
the medium-term effects and costs of psychological 
treatments on maintenance of reduced depression 
symptoms 12 months after treatment. Short-term 
psychoanalytical psychotherapy is as effective as CBT and, 
together with brief psychosocial intervention, offers an 
additional patient choice for psychological therapy, alongside 
CBT, for adolescents with moderate to severe depression who 
are attending routine specialist child and adolescent mental 
health service clinics. 
Introduction
Unipolar major depression is a clinically signiﬁ cant 
mental illness aﬀ ecting a substantial proportion of 
adolescents worldwide.1 Although evidence exists for the 
eﬀ ectiveness of treatments in the short term, data are 
scarce for whether one or more of the available 
psychological treatments is also able to maintain reduced 
depressive symptoms a year after the end of therapy.2,3 This 
issue is not trivial, because maintenance of depressive 
symptoms below a clinical threshold level reduces the risk 
for diagnostic relapse into the adult years.4 Cognitive 
behavioural therapy (CBT) oﬀ ers plausible long-term 
beneﬁ ts for adolescents with depression, and is 
recommended as such by the National Institute for Health 
and Care Excellence (NICE).5 Short-term psychoanalytical 
psychotherapy also shows preliminary promise as a 
treatment for adolescents with depression. CBT has 
established clinical eﬀ ectiveness and relapse prevention, 
and short-term psychoanalytical psychotherapy has shown 
similar clinical eﬀ ectiveness in adults with depression and 
some clinical eﬀ ectiveness in adolescents.6–9
We did the IMPACT trial to assess the medium-term 
eﬀ ects and costs of psychological therapies on maintenance 
of reduced depression symptoms 12 months after 
treatment. We tested a primary superiority hypothesis that 
CBT and short-term psychoanalytical psychotherapy 
would be more likely to maintain signiﬁ cantly lower 
depressive symptoms 1 year after treatment than would a 
reference brief psychosocial intervention. Because our aim 
was to compare two psychological therapies with a brief 
psychosocial intervention, we ﬁ rst established whether 
CBT was inferior to short-term psychoanalytical 
psychotherapy for the same outcomes.
Findings from previous studies10 of psychological 
treatment in adolescents with depression have shown 
reductions in anxiety symptoms even despite no 
reductions in depressive symptoms. Therefore, we 
tested a secondary hypothesis that, compared with 
participants assigned to receive brief psychosocial 
intervention, those assigned to receive CBT or short-
term psychoanalytical psychotherapy would be more 
likely to maintain signiﬁ cantly lower self-reported 
anxiety symptoms, but signiﬁ cantly higher research 
interviewer-evaluated psychosocial function, 1 year after 
treatment. Finally, a cost-eﬀ ectiveness hypothesis tested 
whether the additional costs of CBT and short-term 
psychoanalytical psychotherapy could be justiﬁ ed by 
improvements in clinical eﬀ ectiveness or decreased use 
of health and social care services compared with brief 
psychosocial intervention.
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Method
Study design and participants 
We did this multicentre, pragmatic, single-blind, 
randomised controlled superiority trial in three regions 
of England: East Anglia, a largely rural area of 3 million 
people with four urban areas each containing about 
100 000 people; North London, a densely populated 
urban area with around 4 million people; and the 
North West of England, covering roughly 4 million 
people of whom about 1 million live in rural 
surroundings and 3 million live in the city of Manchester. 
Adolescents (aged 11–17 years) with a diagnosis of 
DSM IV unipolar major depressive disorder were 
recruited from 15 routine National Health Service 
(NHS) child and adolescent mental health service 
(CAMHS) clinics (n=5 in each region).11,12 In the UK 
NHS, adolescents who do not respond to community-
based treatments might be sent to specialist outpatient 
CAMHS. Therefore, the adolescents entered into this 
trial had high numbers of symptoms and concurrent 
personal impairments.
Exclusion criteria were generalised learning diﬃ  culties, 
pervasive developmental disorder, pregnancy, current 
use of another medication that could interact with an 
SSRI, current substance or alcohol abuse disorders, 
previous completion of one of the study treatments, and 
a primary diagnosis of bipolar disorder, schizophrenia, 
or eating disorders. The study was approved by the 
Cambridgeshire 2 Research Ethics Committee (reference 
09/H0308/137) and local NHS provider trusts. The 
protocol has been previously published.13 All patients and 
their parents gave written informed consent.
Randomisation and masking
Patients were randomly assigned (1:1:1), via a web-based 
randomisation service, to receive either CBT or short-term 
psychoanalytical therapy versus the brief psychological 
intervention. Randomisation was done by the trial 
coordinator, with stochastic minimisation by age 
(11–13 years vs 14–15 years vs 16–17 years), sex, self-reported 
depression sum score (≤29 vs 30–39 vs 40–49 vs ≥50),8 and 
region (East Anglia vs North London vs North West 
England). In view of the nature of the interventions, 
patients and clinicians were aware of group allocation, but 
allocation was concealed from outcome assessors.
Procedures
All treatments were manualised; the appendix provides a 
full description of the treatment manuals, including 
theoretical and operational diﬀ erences, and the manuals 
are available online. Short-term psychoanalytical 
psychotherapy comprised a planned programme of 
28 sessions over 30 weeks, with parents or carers oﬀ ered 
up to seven additional sessions by a separate parent 
worker. The techniques of this intervention are based on 
close and detailed observation of the relationship the 
child or young person makes with their therapist. The 
therapist introduces the therapeutic task to the young 
person as one of understanding feelings and diﬃ  culties 
in their life. The therapist is non-judgmental and 
enquiring, and conveys the value of self-understanding. 
Therapists were CAMHS clinicians with child and 
adolescent psychoanalytical psychotherapy training. 
Short-term psychoanalytical psychotherapy has been 
shown to be reliably and eﬀ ectively delivered.9
CBT was based on the classic form originally 
developed for adults with depression.14 We adapted the 
intervention to include parental involvement, focused 
on engagement in therapy, and emphasised the use of 
behavioural techniques. The focus of CBT is to identify 
the behaviours and information processing biases that 
maintain depression and low mood, and to amend 
these through a process of collaborative empiricism 
between the therapist and patient. CBT comprised a 
planned programme of up to 20 sessions over 30 weeks. 
CBT therapists were routine CAMHS clinicians and 
were either clinical psychologists or other clinicians 
who had received post-qualiﬁ cation training in CBT.
The brief psychosocial intervention was derived from 
the routine specialist clinical care delivered in the ADAPT 
trial, and reformulated on the basis of ﬁ ndings suggesting 
this intervention might be clinically eﬀ ective.9 Emphasis 
in the brief psychosocial intervention programme is on 
the importance of psychoeducation about depression, 
in addition to action-oriented, goal-focused, and 
interpersonal activities as therapeutic strategies. Neither 
self-understanding nor cognition change are components 
of the programme. The programme consists of 
12 individual sessions, including up to four family or 
marital sessions delivered over 20 weeks. Therapists were 
drawn from routine CAMHS clinics.
For all three groups, liaison with external agencies and 
personnel (eg, teachers, social care) and peer group was 
commonly done. All therapy sessions were audiotaped. A 
computerised randomisation procedure was used to 
select tapes stratiﬁ ed by age, treatment, and whether 
obtained early (two to four sessions) or later (after four 
sessions) in the therapy. Randomisation was done with 
the Comparative Psychotherapy Process Scale and the 
Brief Psychosocial Intervention scale.15 Independent 
raters rated each treatment session from the 
three treatment modalities to assess treatment ﬁ delity 
and diﬀ erentiation (appendix). In accordance with NICE 
guidelines, ﬂ uoxetine could be added if clinicians 
deemed that combination therapy might accelerate the 
time to remission.5 A test dose of 10 mg was given for 
48 h, followed by 20 mg as a single dose. If no 
improvement was shown within 2–4 weeks, the dose 
could be adjusted upwards to a maximum of 60 mg.
Outcomes
The primary outcome was self-reported depression 
symptoms at weeks 36, 52, and 86 post-randomisation (ie, 
end of treatment), as measured with the Mood and Feelings 
For the treatment manuals see 
http://dev.psychiatry.cam.ac.uk/
projects
See Online for appendix
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Questionnaire (MFQ).16 Secondary outcomes were self-
reported sum scores on the Revised Children’s Manifest 
Anxiety Scale (RMAS), the revised Leyton Obsessional 
Inventory (LOI) for adolescents, and the Health of the 
Nation Outcome Scales for Children and Adolescents—a 
measure of overall current psychosocial impairment.17–19 A 
brief self-reported antisocial behaviour checklist based on 
DSM IV criteria for conduct disorder was used as a binary 
(none, one or more) measure of antisocial behavioural 
symptoms. Presence of major depressive disorder was also 
measured over time by use of the Kiddie-Schedule for 
Aﬀ ective Disorder and Schizophrenia.20 The study was not 
however powered to test a speciﬁ c diagnosis hypothesis. 
Two additional clinical measures were assessed: the 
Columbia Suicide Inventory21 and the self-report Risk and 
Self Harm Inventory.22 Economic measures included the 
Child and Adolescent Service Use Schedule, for collection 
of service and other resource use data, and the EuroQol 5D 
questionnaire 3-level measure of health-related quality of 
life, for calculation of quality-adjusted life-years (QALYs).23,24
Statistical analysis
The appendix details the statistical analysis plan. 
A 2·5% two-sided signiﬁ cance level was used for 
calculation of sample size and interpretation of analyses. 
Clustering of patients by therapist was assumed. 
Five points on the MFQ was taken to represent a clinically 
important diﬀ erence for assessment of superiority, which 
corresponded to an improvement of one point on ﬁ ve of 
the 33 items of the MFQ—ie, a standardised eﬀ ect size of 
0·34 (small to medium), corresponding to non-overlap 
between treatments of about 25%. Data from the ADAPT 
trial gave an estimate of the SD of the primary outcome 
measure (14·6) and correlation between baseline and 
follow-up (0·41).11 We planned for a recruited sample size 
of 540 individuals. With an assumption of 90% follow-up 
(n=486) and a 2·5% signiﬁ cance level to account for 
multiplicity, the power for the comparison of CBT with 
short-term psychoanalytical therapy was 84% if the 
intraclass correlation coeﬃ  cient was zero, 76% if the 
coeﬃ  cient was 0·025, and 69% if the coeﬃ  cient was 0·05.25 
For the comparison of CBT and short-term psychoanalytical 
therapy with brief psychological intervention, the power 
was 93%, 88%, and 82% for an intraclass correlation 
coeﬃ  cient of 0·0, 0·025, or 0·05, respectively.25
The marginal treatment eﬀ ect was estimated with a 
linear mixed model, with a random eﬀ ect for therapist, 
patient, and slope. To prevent bias due to assessments 
being delayed, time since randomisation was used as a 
continuous variable in a longitudinal mixed model 
(appendix). Diagnosis of major depressive disorder 
(present vs absent) was analysed with a logistic 
generalised estimating equation model over the same 
time period. To investigate non-response, a logistic 
generalised estimating equation model was ﬁ tted to an 
indicator variable for missing primary outcome data. All 
analyses included ﬁ xed covariates prespeciﬁ ed at 
baseline: MFQ, RMAS, LOI, Antisocial Behaviour 
Questionnaire (ABQ) scores, treatment allocation, 
region, sex, age at randomisation, comorbid behaviour 
disorder, and prescription of SSRI before trial entry 
(appendix).
There are no standardised methods for measuring the 
adverse eﬀ ects of psychological treatments given to 
adolescents with depression. We derived a physical 
adversities score from self-reported items of breathing 
problems, sleep disturbances, drowsiness or tiredness, 
nausea, sweating, and being restless or overactive rated 
present or absent.
Methods of the economic evaluation have been 
applied previously26 and are shown in the appendix 
and available online. In brief, cost-eﬀ ectiveness was 
explored at the 86 week follow-up point, with outcomes 
expressed as QALYs and costs assessed from a service 
perspective (health, social care, and education). Unit 
costs were for the ﬁ nancial year 2011–12, and costs 
and QALYs were discounted at a rate of 3·5% as 
recommended by NICE.27 Diﬀ erences in mean costs 
were tested with linear regression models, with validity 
of the results conﬁ rmed with bias-corrected, non-
parametric bootstrapping (5000 resamples).25 For the 
cost-eﬀ ectiveness analysis, we calculated incremental 
cost-eﬀ ectiveness ratios (the diﬀ erence in mean cost 
divided by the diﬀ erence in mean eﬀ ect) and explored 
uncertainty with cost-eﬀ ectiveness acceptability curves, 
which show the probability that each of the treatments 
is the optimum choice, for a range of possible values of 
willingness to pay for additional QALYs.28 All economic 
analyses were adjusted for the prespeciﬁ ed covariates 
and for baseline utility and cost, as appropriate. 
Complete case analysis was used, with the eﬀ ect of 
missing data and sessions oﬀ ered but not attended 
explored in sensitivity analyses.
We did analysis by intention to treat, subject to the 
availability of data. Analyses were done with Stata 
(version 12.0). This trial is registered with Current 
Controlled Trials, number ISRCTN83033550.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between June 29, 2010, and Jan 17, 2013, we randomly 
assigned 470 patients to receive the brief psychosocial 
intervention (n=158), CBT (n=155), or short-term 
psychoanalytical therapy (n=157; ﬁ gure). Five patients 
withdrew before starting treatment and requested data be 
deleted; the remaining 465 participants comprised the 
intention-to-treat population (ﬁ gure). The patient 
recruitment rate was 40% in East Anglia, 33% in the 
For methods of the economic 
evaluation see 
http://dev.psychiatry.cam.ac.uk/
projects
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North West, and 27% in North London (table 1). 
63 therapists delivered the brief psychosocial intervention, 
44 therapists delivered CBT, and 38 therapists delivered 
short-term psychoanalytical therapy. Most (n=53) brief 
psychosocial intervention therapists were either 
psychiatrists who had passed postgraduate general 
training (ie, obtained membership of the Royal College of 
Psychiatrists) and subsequently entered specialist 
CAMHS psychiatry training or consultants. The primary 
analysis population comprised 392 (84%) patients who 
provided one or more self-reported depression symptom 
scores at weeks 36, 52, and 86 (ﬁ gure). 39 (10%) patients 
had one MFQ score, 90 (23%) had two MFQ scores, and 
263 (67%) had three MFQ scores. The number of patients 
with follow-up data for secondary outcomes was similar 
between treatment groups. The data available were within 
the margins suggested by the power calculation. Baseline 
characteristics were similar between groups (table 1).
The appendix shows the full proﬁ le of depression 
symptoms at baseline (appendix). The mean number of 
symptoms was 8·4 (SD 2·5) in patients undergoing 
brief psychosocial intervention, 8·7 (2·3) in patients 
undergoing CBT, and 8·3 (2·5) in patients undergoing 
short-term psychoanalytical therapy (appendix). The most 
prevalent symptom was sleep disturbance (n=427 [92%]) 
followed by depressed mood (n=390 [84%]; appendix). 
Psychotic symptoms were uncommon (n=48 [10%]), but a 
notable number of patients had current suicidal ideas 
(n=284 [61%]) and lifetime suicide attempts (n=177 [38%]; 
appendix). Symptom prevalence rates were similar 
between treatment groups (appendix). 225 (48%) patients 
had concurrent comorbid psychiatric disorders: 71 (46%) 
in the brief psychosocial intervention group, 80 (52%) 
in the CBT group, and 74 (47%) in the short-term 
psychoanalytical therapy group (appendix). Overall, 134 
(29%) patients had one comorbidity, 60 (13%) patients had 
two comorbidities, and 31 (7%) patients had three or more 
comorbidities, with no marked diﬀ erences between 
groups. Non-suicidal self-injury in the previous 2 weeks 
was reported in 85 (18%) patients: 26 (17%) assigned to the 
brief psychosocial intervention, 25 (16%) assigned to CBT, 
and 34 (22%) assigned to short-term psycho analytical 
Figure: Trial proﬁ le
BPI=brief psychological intervention. CBT=cognitive behavioural therapy. STPP=short-term psychoanalytical psychotherapy. *The primary hypothesis was analysed in 
392 (84%) of 465 patients who were randomised, accepted treatment, and provided one or more self-reported depression symptom score over the 36, 52, or 86 week 
assessment points. Five patients withdrew consent before starting treatment (n=3 in the BPI group, n=1 each in the CBT and STPP groups) and requested their data be deleted.
470 randomly assigned
557 participants screened for eligibility
87 excluded
73 did not meet criteria for moderate to severe depression
4 had mania
4 had a substance use disorder
2 had received previous treatment
1 had autism
1 was pregnant
1 would not engage with assessor
1 was unable to read or understand information
157 allocated to STPP group
136 received allocated intervention
21 did not receive treatment 
15 did not attend sessions
2 at clinical decision to change case 
management
2 withdrawn by mother
1 had transport problems
1 because therapist felt treatment was 
inappropriate
155 allocated to CBT group
142 received allocated intervention
13 did not receive treatment 
8 did not attend sessions
3 withdrew
1 because therapist felt the patient was
better
1 withdrew because of waiting time
158 allocated to BPI group
147 received allocated intervention
11 did not receive treatment 
8 did not attend sessions
1 because parent felt the patient was
better
1 started private treatment
1 withdrew
102 had 6 week follow-up data
111 had 12 week follow-up data
106 had 36 week follow-up data
105 had 56 week follow-up data
123 had 86 week follow-up data
99 had 6 week follow-up data
108 had 12 week follow-up data
105 had 36 week follow-up data
110 had 56 week follow-up data
130 had 86 week follow-up data
108 had 6 week follow-up data
108 had 12 week follow-up data
110 had 36 week follow-up data
110 had 56 week follow-up data
119 had 86 week follow-up data
155 comprised the intention-to-treat population
132 had available data for primary analysis*
154 comprised the intention-to-treat population
133 had available data for primary analysis*
156 comprised the intention-to-treat population
127 had available data for primary analysis*
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therapy; lifetime non-suicidal self-injury was reported in 
246 (53%) participants: 87 (56%), 75 (49%), and 84 (54%), 
respectively.
The number of patients starting therapy was 147 (93%) 
in the brief psychosocial intervention group, 142 (92%) in 
the CBT group, and 136 (87%) in the short-term 
psychoanalytical therapy group, with no diﬀ erences in 
proportions between groups (χ² p=0·203). The number of 
individual treatment sessions given per group was less 
than planned (median six [IQR four to 11] in the brief 
psychosocial intervention group, nine [ﬁ ve to 14] in the 
CBT group, and 11 [ﬁ ve to 23] in the short-term 
psychoanalytical therapy group), but diﬀ ered signiﬁ cantly 
between groups (Kruskal–Wallis p<0·0001; appendix). Of 
patients assigned to receive the brief psychosocial 
intervention, 24 (17%) had more sessions than the manual 
speciﬁ ed, compared with ﬁ ve (3%) assigned to receive 
CBT and three (2%) assigned to receive short-term 
psychoanalytical therapy. Mean duration of therapy did 
not diﬀ er signiﬁ cantly between treatment groups 
(27·5 weeks [SD 21·5] in the brief psychosocial 
intervention group, 24·9 weeks (SD 17·7) in the CBT 
group, 27·9 weeks [16·8] in the short-term psychoanalytical 
therapy group; Kruskal–Wallis p=0·238).
Raters assessed treatment ﬁ delity by use of 232 audio 
tapes: 75 tapes for brief psychosocial intervention sessions, 
76 tapes for CBT sessions, and 81 tapes for short-term 
psychoanalytical therapy sessions. Overall, 60 (81%) brief 
psychosocial intervention sessions, 61 (80%) short-term 
psychoanalytical therapy sessions, and 60 (74%) CBT 
sessions met treatment ﬁ delity criteria (appendix). 
Treatment diﬀ erentiation was good: the mean cognitive 
behavioural subscale score on the Comparative 
Psychotherapy Process Scale was 1·91 (95% CI 1·73–2·09) 
higher for CBT sessions than for short-term psycho-
analytical therapy sessions (p<0·0001), whereas the 
mean psychodynamic interpersonal subscale score was 
1·18 (1·01–1·30) higher for short-term psychoanalytical 
therapy sessions than for CBT sessions (p<0·0001). 
Patients attending brief psychosocial intervention sessions 
had a signiﬁ  cantly lower mean score on the cognitive 
behavioural subscale than did those attending CBT 
sessions (mean diﬀ erence –0·93, 95% CI –1·12 to –0·75; 
p<0·0001) and a signiﬁ cantly lower mean score on the 
psychodynamic interpersonal subscale than did those 
attending short-term psychoanalytical therapy sessions 
(–1·30, –1·48 to –1·11; p<0·0001).
The number of patients receiving an SSRI before 
randomisation was 29 (19%) in the brief psychosocial 
intervention group, 32 (21%) in the CBT group, and 
28 (18%) in the short-term psychoanalytical therapy 
group; by the end of study, the number of patients who 
reported having received an SSRI at any time over the 
course of the trial (randomisation up to 86 weeks) was 
56 (41%), 55 (40%), and 50 (36%), respectively (p=0·729; 
appendix).
Behavioural disorder at baseline was found to predict 
non-response. Because this was not a prespeciﬁ ed 
baseline covariate, it was added to all models of outcome 
to support the missing-at-random assumption. The 
appendix provides data for time from randomisation to 
assessment and estimates of the main eﬀ ect and time 
with treatment interaction.
 The primary outcome of self-reported depression 
symptoms (MFQ) at weeks 36, 52, and 86 did not diﬀ er 
signiﬁ cantly between patients in the CBT group and those 
in the short-term psychoanalytical therapy group, nor 
between those in the CBT or short-term psycho analytical 
therapy groups combined versus the brief psychological 
intervention group (table 2). With a lower score 
representing improved outcome, we recorded a larger 
diﬀ erence in favour of combined established treatments at 
weeks 36 and 52 (table 2), but these reductions were not 
statistically signiﬁ cant, less than the ﬁ ve unit diﬀ erence 
prespeciﬁ ed as clinically meaningful, and not accompanied 
by diﬀ erences in psychosocial impairment. The secondary 
outcomes of anxiety and obsessional symptoms were 
signiﬁ cantly reduced after the psychological treatments 
combined versus brief psychosocial therapy at week 36 
only (table 2). The therapist intracluster correlation 
coeﬃ  cient for therapy outcomes was calculated as the 
BPI (n=155) CBT (n=154) STPP (n=156)
Age (years) 15 (11–17) 15 (12–17) 15 (11–17)
Sex
Male 40 (26%) 40 (26%) 37 (24%)
Female 115 (74%) 114 (74%) 119 (76%)
Ethnic origin
White* 121/147 (82%) 131/152 (86%) 130/151 (86%)
Region
East Anglia 61 (39%) 62 (40%) 62 (40%)
North London 43 (28%) 41 (27%) 43 (27%)
North West 51 (33%) 51 (33%) 51 (33%)
Conduct or oppositional disorder 20 (13%) 20 (13%) 16 (10%)
Self-reported depression score 46·2 (10·6) 46·2 (10·3) 45·4(10·8)
Number of Interviewer-assessed depressive 
symptoms
8·4 (2·5) 8·7 (2·3) 8·3 (2·5)
SSRI prescribed before trial entry† 29/153 (19%) 32/125 (21%) 28/155 (18%)
Prevalence of one or more comorbid DSM-5 
axis 1 psychiatric diagnoses
71 (46%) 80 (52%) 74 (47%)
One or more recent suicide attempts‡ 3 (2%) 2 (1%) 7 (5%)
Lifetime suicide attempts 57 (37%) 48 (31%) 55 (35%)
Recent self-harm attempts‡ 26 (17%) 25 (16%) 34 (22%)
One or more lifetime non-suicidal self-injury 
episodes
87 (56%) 75 (49%) 84 (54%)
HoNOSCA score 18·9 (6·0) 18·4(6·0) 18·3 (6·3)
EQ-5D score 0·596 (0·27) 0·578 (0·58) 0·569 (0·59)
Data are median (range), n (%), or mean (SD). BPI=brief psychological intervention. CBT=cognitive behavioural 
therapy. STPP=short-term psychoanalytical psychotherapy. HoNOSCA=Health of the Nation Outcome Scales for 
Children and Adolescents. EQ-5D=EuroQol ﬁ ve dimensions questionnaire. *Excludes 15 patients for whom ethnic 
group or origin was not stated or missing. †Excludes ﬁ ve patients with missing information. ‡In the previous 2 weeks.
Table 1: Baseline characteristics 
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proportion of the random intercept variance, and was 
negligible (<10–⁷) for all the models (data not shown). Study 
power was therefore at the upper end of the range, because 
the sample size calculation included a range of values of 
the intracluster correlation coeﬃ  cient, from 0 to 0·05.
Table 3 shows ﬁ ndings for the secondary binary 
outcomes of patients who self-reported no or one or more 
antisocial behaviour symptoms and patients who met 
clinical diagnostic criteria for major depressive disorder. 
Compared with brief psychosocial intervention, CBT and 
short-term psychoanalytical therapy led to signiﬁ cantly 
lower self-reported ABQ scores at week 36, but this 
diﬀ erence was not maintained at week 52.
Over the follow-up period, recent suicide attempts 
were reported in three (3%) of 279 patients at 36 weeks 
(n=1 per group), two (6%) of 201 patients at 52 weeks 
(n=1 in the brief psychosocial intervention group, n=1 in 
the short-term psychoanalytical therapy group), and no 
patients at 86 weeks, compared with 12 (3%) of 
465 patients at baseline (table 1). Similarly, non-suicidal 
self-injury attempts were reported in 19 (7%) of 
268 patients at 36 weeks (n=10 in the brief psychosocial 
intervention group, n=6 in the CBT group, n=3 in the 
short-term psychoanalytical therapy group), 14 (4%) of 
234 patients at 52 weeks (n=6, n= 2, n=6, respectively), 
and 16 (5%) of 257 at 86 weeks (n=7, n=5, n=4, 
BPI CBT STPP STPP vs CBT CBT plus STPP vs BPI
n Mean (SD) n Mean (SD) n Mean (SD) Treatment eﬀ ect (95% CI)* p 
value†
Treatment eﬀ ect (95% CI)* p 
value†
Primary
MFQ
Baseline 155 46·2 (10·6) 154 46·2 (10·3) 156 45·4 (10·8) ·· ·· ·· ··
6 weeks 99 36·5 (14·3) 104 35·2 (11·3) 107 34·9 (13·2) ·· ·· ·· ··
12 weeks 112 34·1 (14·4) 106 31·6 (13·3) 108 33·1 (14·2) ·· ·· ·· ··
36 weeks 105 30·5 (16·1) 104 24·2 (15·1) 109 26·6 (15·7) 0·179 (–3·731 to 4·088) 0·929 –3·234 (–6·611 to 0·143) 0·061
52 weeks 105 25·1 (16·2) 111 25·0 (18·0) 110 23·0 (15·9) 0·307 ( –3·161 to 3·774) 0·862 –2·806 (–5·790 to 0·177) 0·065
86 weeks 116 23·6 (16·2) 123 22·3 (15·7) 114 21·8 (15·5) 0·578 ( –2·948 to 4·104) 0·748 –1·898 (–4·922 to 1·126) 0·219
Secondary
RCMAS
Baseline 155 41·1 (7·6) 154 41·2 (6·4) 155 40·5 (7·7) ·· ·· ·· ··
6 weeks 98 35·9 (10·6) 103 37·1 (7·9) 107 36·7 (10·0) ·· ·· ·· ··
12 weeks 110 34·2 (11·9) 105 34·4 (11·4) 108 34·3 (11·9) ·· ·· ·· ··
36 weeks 104 32 (13·3) 102 27·0 (13·7) 107 28·6 (13·3) 0·855 (–2·530 to 4·239) 0·621 –3·832 (–6·781 to –0·884) 0·011
52 weeks 100 27·2 (14·8) 108 26·4 (14·9) 104 25·5 (14·5) 0·663 (–2·354 to 3·680) 0·667 –2·818 (–5·432 to –0·205) 0·035
86 weeks 109 24·7 (14·7) 115 24·8 (15·4) 108 23·8 (14·6) 0·254 (–2·980 to 3·489) 0·878 –0·663 (–3·460 to 2·134) 0·642
LOI
Baseline 155 10·0 (5·3) 152 10·8 (5·4) 154 9·2 (5·0) ·· ·· ·· ··
6 weeks 98 7·8 (5·4) 102 7·6 (5·0) 107 7·6 (5·0) ·· ·· ·· ··
12 weeks 111 6·6 (5·6) 104 6·7 (5·2) 107 7·3 (5·1) ·· ·· ·· ··
36 weeks 103 6·3 (5·4) 101 4·8 (4·8) 107 5·2 (4·9) –0·816 (–1·972 to 0·341) 0·167 –1·249 (–2·258 to –0·240) 0·015
52 weeks 99 5·6 (5·8) 107 5·1 (5·5) 102 4·9 (4·7) –0·574 (–1·601 to 0·452) 0·273 –1·120 (–2·010 to –0·231) 0·014
86 weeks 107 5·0 (5·4) 115 4·9 (5·0) 106 4·0 (4·6) –0·062 (–1·091 to 0·967) 0·906 –0·847 (–1·736 to 0 ·042) 0·062
HoNOSCA
Baseline 148 18·9 (6·0) 143 18·4 (6·0) 144 18·2 (6·3) ·· ·· ·· ··
6 weeks 88 14·5 (6·5) 91 14·1 (6·4) 96 14·6 (6·9) ·· ·· ·· ··
12 weeks 101 14·3 (7·5) 96 11·9 (6·8) 94 12·9 (6·2) ·· ·· ·· ··
36 weeks 88 12 (8·7) 81 9·7 (7·2) 88 10·3 (7·6) 0·617 (–1·499 to 2·733) 0·567 –1·410 (–3·221 to 0·401) 0·127
52 weeks 88 9·5 (6·9) 86 8·5 (7·3) 83 8·6 (5·8) 0·620 (–1·078 to 2·318) 0·474 –1·154 (–2·601 to 0·293) 0·118
86 weeks 98 8·2 (6·2) 92 7·3 (5·2) 85 8·2 (7·2) 0·626 (–0·814 to 2·066) 0·394 –0·611 (–1·819 to 0·598) 0·322
Linear mixed model estimates of the treatment eﬀ ect at weeks 36, 52, and 86 post-randomisation. Data were missing for some participants. The model was based on data for 
392 (84%) of 465 patients who provided one or more self-reported depression symptom scores over the 36, 52, or 86 week assessment points. The analysis used time since 
randomisation as a continuous variable, with therapist, participant and slope random eﬀ ects, treatment, treatment by time interaction, and other prespeciﬁ ed baseline 
covariates (appendix). BPI=brief psychological intervention. CBT=cognitive behavioural therapy. STPP=short-term psychoanalytical psychotherapy. MFQ=Mood and Feelings 
Questionnaire. RCMAS=Revised Children’s Manifest Anxiety Scale. LOI=Leyton Obsessional Inventory–adolescent version. HoNOSCA=Health of the Nation Outcome Scale for 
Children and Adolescents. *The marginal mean diﬀ erence at a given timepoint, with negative eﬀ ects indicating treatment beneﬁ t. †To control for two comparisons, we used a 
2·5% signiﬁ cance level to maintain a 5% signiﬁ cance level for any measure and timepoint combination. 
Table 2: Primary and secondary outcomes
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respectively), which compares favourably with self-harm 
attempts reported at baseline (n=85 [18%]; table 1). On 
the basis of our physical adversities score, we recorded a 
decline in the self-reporting of adverse physical events 
over the course of the study, with no observable 
diﬀ erences between treatment groups (table 4).
The proportion of patients in diagnostic remission by 
36, 52, or 86 weeks did not diﬀ er signiﬁ cantly between 
groups (data not shown). Because the present study is 
pragmatic, with no control group, we did a comparison of 
the 12 week remission rate with the rate in the TADS 
study,3 which included a pill placebo control group 
(n=111): 145 (48%) of 305 patients were in remission at 
12 weeks in our study compared with 37 (34%) placebo 
patients in the TADS study. Additionally, in the treatment 
trial of resistant depression in adolescents,29 203 (61%) of 
334 patients were in diagnostic remission by week 72 
compared with 221 (77%) of 286 by week 86 in this study. 
Finally, 15 (11%) of the 140 patients in remission at 
week 36 had relapsed by week 86 (n=5/48 [10%] in the 
brief psychosocial intervention group, n=4/49 [8%] in the 
CBT group, n=2/48 [4%] in the short-term psychoanalytical 
therapy group; p=0·149).
The cost of the trial interventions was lowest for 
CBT (mean £904·57 [SD 607·25]) and highest for short-
term psychoanalytical therapy (£1396·72 [1133·41]), with 
the brief psychosocial intervention costing a mean of 
£1292·91 (851·29; appendix). The costs of use of all other 
services (health, social care, and education) diﬀ ered little 
between patients in the brief psychosocial intervention 
group (mean £1385·4 [SD 2807·7]), the CBT group 
(£1459·26 [3481·02]), and the short-term psychoanalytical 
therapy group (£1668·51 [3425·68]) over 86 weeks 
(appendix). The total combined cost of trial interventions 
and use of other services was £2678·39 (SD 2678·39) for 
the brief psychosocial intervention, £2379·01 (3643·85) 
for CBT, and £3081·70 (3573·17) for short-term psycho-
analytical therapy; neither these costs, nor QALYs 
(mean 1·241 [SD 0·270], 1·228 [0·304], and 1·246 [0·293] 
QALYs, respectively), diﬀ ered signiﬁ cantly between 
groups over 86 weeks (appendix). No evidence supported 
the superior cost-eﬀ ectiveness of short-term psycho-
analytical therapy compared with brief psychosocial 
intervention or CBT, or CBT compared with brief 
psychosocial intervention (appendix).
Discussion
We found no evidence for the superiority of CBT or 
short-term psychoanalytical therapy compared with a 
brief psychosocial intervention for maintenance of 
reduced depression symptoms 12 months after 
treatment. To our knowledge, this is the ﬁ rst trial to 
show that short-term psychoanalytical therapy and brief 
psychosocial intervention are as clinically eﬀ ective as 
CBT for the treatment of adolescents with depression. 
We note the continuing decline of symptoms and further 
increase in remission, which are not explained by any 
marked diﬀ erences in post-treatment service use, costs 
between therapies, or reported SSRI use. However, 
caution is required with the ﬁ ndings for remission 
because the study was not powered for treatment group 
comparisons, interview data were missing at each 
BPI (n=155) CBT (n=154) STPP (n=156) STPP vs CBT CBT plus STPP vs BPI
Treatment eﬀ ect (95% CI)* p value† Treatment eﬀ ect (95% CI)* p value†
MDD
Baseline 155 (100%) 154 (100%) 156 (100%) ·· ·· ·· ··
6 weeks 63/143 (44%) 57/95 (60%) 62/99 (63%) ·· ·· ·· ··
12 weeks 57/ 105 (54%) 46/98 (47%) 54/99 (55%) ·· ·· ·· ··
36 weeks 42/95 (44%) 28/89 (31%) 35/98 (36%) –0·064 (–0·206 to 0·078) 0·375 –0·043 (–0·160 to 0·073) 0·465
52 weeks 27/92 (29%) 23/90 (26%) 23/87 (27%) –0·018 (–0·120 to 0·084) 0·727 –0·053 (–0·142 to 0·035) 0·239
86 weeks 27/99 (27%) 24/95 (25%) 14/92 (15%) 0·057 (–0·043 to 0·157) 0·261 –0·065 (–0·152 to 0·022) 0·145
ABQ
Baseline 121 (78%) 124/152 (82%) 128/154 (83%) ·· ·· ·· ··
6 weeks 75/98 (77%) 71/102 (70%) 73/107 (68%) ·· ·· ·· ··
12 weeks 78/111 (70%) 57/104 (55%) 52/107 (49%) ·· ·· ·· ··
36 weeks 62/103 (60%) 45/101 (45%) 55/107 (51%) –0·068 (–0·186 to 0·051) 0·263 –0·128 (–0·238 to –0·019) 0·022
52 weeks 47/99 (47%) 43/107 (40%) 41/102 (40%) –0·040 (–0·135 to 0·055) 0·408 –0·074 (–0·163 to 0·015) 0·102
86 weeks 39/107 (36%) 49/115 (43%) 43/106 (41%) 0·018 (–0·083 to 0·120) 0·725 0·040 (–0·051 to 0·131) 0·389
Data are n (%) or n/N (%), unless otherwise speciﬁ ed. Logistic generalised estimated equation model estimates of the treatment eﬀ ect at weeks 36, 52, and 86 
post-randomisation. The model was based on data from 36 weeks post-randomisation, with therapist, participant and slope random eﬀ ects, treatment, treatment by time 
interaction, and other prespeciﬁ ed baseline covariates. BPI=brief psychological intervention. CBT=cognitive behavioural therapy. STPP=short-term psychoanalytical 
psychotherapy. MDD=major depressive disorder. ABQ=Antisocial Behaviour Questionnaire. *The marginal mean diﬀ erence at a given timepoint, with negative eﬀ ects 
indicating treatment beneﬁ t. The study was not powered to test for treatment diﬀ erences in clinical diagnostic relapse. †To control for two comparisons, we used a 2·5% 
signiﬁ cance level to maintain a 5% signiﬁ cance level for any measure and timepoint combination. 
Table 3: Patients with an MDD diagnosis and one or more antisocial behaviour symptoms
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timepoint, and the control comparison could only be 
achieved at 12 weeks. We also note the small reduction 
in symptoms in favour of established treatments at the 
end (36 weeks) of treatment, but not by end of study, 
which is consistent with previous reports of psychological 
treatment eﬀ ects on reducing anxiety in patients with 
depression.10 No participants reported increases in 
suicidal ideation, non-suicidal self-injury, or adverse 
physical side-eﬀ ects during the study.
Three previous randomised controlled trials similar in 
design to the present study have reported follow-up data 
beyond end of treatment. Birmaher and colleagues30 
reassessed 107 adolescents with major depressive 
disorder 2 years after treatment with CBT, systematic 
behavioural family therapy, or non-directive supportive 
therapy. There were no diﬀ erences in outcome by 
original treatment group. A naturalistic follow-up study31 
of 196 adolescents with depression (45% of the original 
sample) recruited to a treatment trial reported that 5 year 
post-trial recurrence was more likely in participants with 
higher depressive symptom scores at the end of 
treatment, but was not associated with treatment type. 
Most recently, a 6 year follow-up study32 of a cognitive 
behaviour programme aimed at prevention of depressive 
episodes showed that the strongest eﬀ ect was early and 
better maintained with additional booster sessions and 
treatment of parental depression. Overall these ﬁ ndings 
are consistent in their suggestion that early response to 
treatment can be followed by continued improvement 
across diﬀ erent treatment modalities. The absence of 
diﬀ erence between the three treatments assessed in the 
present study might be due to a putative shared common 
eﬀ ect, but could also be a result of alternative 
explanations, including three unique eﬀ ects leading to 
the same outcome or even to no eﬀ ect, with the decline 
in symptoms being due to change over time.
Reports of non-response to treatment in 21–25% of 
trial patients are also consistent with these results.3,11,28–30 
Such non-response might be due to issues of selection of 
the right treatment for the right patient, noting the 
likelihood of resistance to a given treatment early in 
therapy, or to prediction of the likelihood of non-
compliance. One challenge for further research is to 
improve the precision of the ability to select the best 
treatment for a given patient with depression. Despite 
the planned diﬀ erences in treatment intensity, in 
practice, young people attended a median of six to 11 
sessions over 25–28 weeks across all three treatment 
groups. A ﬁ rst course of therapy for adolescents with 
depression could be brief (six to 11 sessions) and at no 
diﬀ erence in cost between the available treatment options 
assessed in this trial. The reasons for non-attendance 
deserve further investigation.
Our study had various strengths, including that 
participants were representative of the population with 
moderate to severe depression, with self-harm, 
suicidality, and non-depressive comorbid disorders at 
the point of referral; CAMHS referral across diverse 
regions of the UK; meeting of research diagnostic 
criteria for DSM IV major depressive disorder; and 
randomisation done remotely from the research team. 
There was a loss to follow-up, but data for the primary 
outcome measure (MFQ) were available in 84% of 
participants. The overall sample size was greater than in 
previous studies, and this is the ﬁ rst time a trial of 
adolescents with depression has been designed to follow 
up participants for 52 weeks after the end of treatment. 
Each of the three treatments was manualised, 
interventions were delivered as expected, and clear 
diﬀ erences in approach were maintained between 
therapies. Some patients in all three groups received 
antidepressant medication. This characteristic 
strengthens generalisability, but restricts the 
interpretation of the ﬁ ndings. Methods of prescribing 
did not diﬀ er between groups over the course of the 
study, and ﬂ uoxetine was prescribed both during and 
after the end of treatment. Neither the reasons for 
prescribing nor medication compliance were controlled 
for over the study course; therefore, we cannot exclude 
the possibility that SSRIs might have contributed to the 
improvements over time. Furthermore, the declines in 
symptoms and improvements in wellbeing could be a 
function of time. The absence of a no-treatment control 
group restricts the assertion that any therapy was 
causally eﬀ ective. The economic results were limited by 
missing data, which was higher than for the primary 
clinical outcome measure (40%). Multiple imputation of 
missing data did not, however, change the economic 
results of the analysis. Future research should focus on 
psychological mechanisms associated with treatment 
response, the maintenance of positive eﬀ ects, non-
response, and whether or not brief psychotherapies are 
of use in community and primary care settings.
In summary, brief psychosocial intervention, CBT, 
and short-term psychoanalytical therapy are all 
associated with maintenance of reduced depression 
symptoms 1 year after the end of treatment. Short-term 
BPI CBT STPP
n Mean 
(SD)
Median 
(min–max 
range)
n Mean 
(SD)
Median 
(min–max 
range)
n Mean 
(SD)
Median 
(min–max 
range)
Baseline 155 5·0 (1·1) 5 (1–6) 154 5·1 (1·0) 5 (2–6) 156 5·0 (1·1) 5 (2–6)
6 weeks 99 4·4 (1·5) 5 (0–6) 104 4·6 (1·3) 5 (2–6) 107 4·4 (1·5) 5 (0–6)
12 weeks 112 4·2 (1·6) 4 (0–6) 106 4·0 (1·5) 4 (0–6) 108 4·2 (1·6) 4 (0–6)
36 weeks 105 4·1 (1·6) 4 (0–6) 104 3·6 (1·6) 4 (0–6) 109 3·6 (1·7) 4 (0–6)
52 weeks 105 3·5 (1·8) 3·5 (0–6) 111 3·5 (1·9) 4 (0–6) 110 3·2 (1·9) 3 (0–6)
86 weeks 116 3·3 (1·8) 3·5 (0–6) 123 3·4 (1·9) 4 (0–6) 114 3·2 (1·8) 3 (0–6)
We derived a physical adversities scores based on six self-reported adverse items: breathing problems, sleep disturbances, 
drowsiness or tiredness, nausea, sweating, and being restless or overactive rated present or absent. BPI=brief 
psychological intervention. CBT=cognitive behavioural therapy. STPP=short-term psychoanalytical psychotherapy. 
Table 4: Adverse event scores 
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psychoanalytical therapy and brief psychosocial inter-
ventions oﬀ er additional patient choice, alongside CBT, 
for depressed adolescents attending routine specialist 
CAMHS clinics.
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